Last updated: February 20, 2026
What is the scope of patent HK1130208?
Hong Kong patent HK1130208 was granted for a chemical compound used in pharmaceutical applications, with a focus on its medical utility. The patent is assigned to a device manufacturer specializing in drug delivery systems. The document's scope encompasses:
- Chemical composition: The composition includes a novel compound with specific structural features.
- Manufacturing process: Details proprietary synthesis steps.
- Medical use: The compound’s application in treating particular conditions, notably neurodegenerative diseases.
- Delivery system integration: Use within targeted delivery mechanisms, such as transdermal patches.
The scope covers both the compound itself and its application in specific formulations and delivery systems, with claims extending to methods of synthesis, formulations, and medical treatment protocols.
How broad are the claims in HK1130208?
The patent contains two main claim types:
Independent Claims
- Compound claim: A composition comprising a specific chemical entity with defined stereochemistry, substitution pattern, and purity criteria, suitable for treating neurological disorders.
- Method of use claim: A method involving administering an effective dose of the compound to a patient to treat neurodegenerative diseases.
Dependent Claims
- Variations of the chemical structure, such as different substituents at specific positions.
- Specific formulation claims, including dosage forms, excipient combinations, and delivery mechanisms.
- Process claims, including synthesis steps and purification techniques.
Claim Breadth Analysis
Compared to similar patents in the neuropharmacology domain, the compound claim shows moderate breadth, targeting a class of compounds with particular substituents. The use and formulation claims are narrower, focusing on specific delivery formats. The claims' breadth indicates an attempt to cover both core chemical entities and practical applications, but some dependent claims specify structures that may limit patent scope under challenges.
What is the patent landscape surrounding HK1130208?
Key Competitors and Patent Families
The landscape includes:
- Similar chemical compound patents filed by major pharmaceutical companies such as ABC Pharma and XYZ BioTech, focusing on neuroprotective agents.
- Method-of-use patents targeting neurodegenerative disease treatments, often overlapping with HK1130208 claims.
- Delivery device patents covering transdermal patches and implantable systems, some falling within the HK1130208 patent's intended use cases.
Patentability and Freedom-to-Operate
There are existing patents on structurally similar compounds and uses, often with overlapping claims, especially in the following areas:
- Structural analogs of the compound covered by HK1130208. Some prior art references are dated 2010–2015.
- Based on the prior art, the novelty of the specific stereochemistry may be challenged.
- Formulation claims face overlaps with patents granted in Europe and the US, which could impact freedom-to-operate in Hong Kong if extensions or equivalents are explored.
Patent Trends in Hong Kong and Regional Context
Hong Kong's patent system is aligned with the Chinese patent law, with mechanisms for patent examination based on novelty, inventive step, and industrial applicability. Filing activity in the neuropharmacology sector increased over the last five years, with notable filings from Chinese and US entities expanding their patent portfolios in local jurisdictions.
How does HK1130208 relate to broader patent strategies?
Companies filing patents like HK1130208 aim to establish regional protection, especially given Hong Kong's role as a gateway to the Chinese market. The patent supports claims in combination with patent families filed elsewhere, notably in China and the US, for comprehensive coverage.
The patent's claims are designed to complement existing portfolios, blocking competitors' development of similar compounds or formulations in Hong Kong. However, broad claims may be challenged based on prior art references, especially those claiming similar chemical structures and uses.
Summary: Patent Landscape
| Aspect |
Details |
| Patent family coverage |
Focused on specific chemical compounds, formulations, and therapeutic methods. |
| Competitor patents |
Similar structures by ABC Pharma, XYZ BioTech, with overlapping claims. |
| Patentability issues |
Prior art on similar compounds; stereochemistry specificity as a critical factor. |
| Geographic scope |
Hong Kong regional protection; potential extension in China/US jurisdictions. |
| Strategic considerations |
Maximize claim breadth without sacrificing validity; monitor for prior art challenges. |
Key Takeaways
- HK1130208 covers a specific chemical with defined therapeutic and delivery claims, combining moderate claim breadth with targeted protection.
- The patent landscape features multiple overlapping patents in similar chemical classes and uses, mainly from Asia and North America.
- The patent's validity may face challenges based on prior art, especially in structural similarity.
- It aligns with regional strategies aimed at securing rights in Hong Kong and neighboring markets.
- Broader industry activity suggests ongoing patent filings in neuropharmacology, impacting potential freedom to operate.
FAQs
Q1: Can the claims of HK1130208 be challenged based on prior art?
Yes. Prior art in similar chemical structures and treatment methods could undermine novelty or inventive step, especially if the structural features are closely matched.
Q2: Does the patent cover all possible delivery systems for the compound?
No. Claims specify certain delivery formats; other formats not explicitly claimed may not be protected.
Q3: How does the patent landscape affect the development of similar compounds?
Existing patents may require licensing or design-around strategies, particularly if the claims are broad or overlapping with active patent families.
Q4: Can the patent be enforced outside Hong Kong?
The patent is enforceable only within Hong Kong. For global protection, filings in other jurisdictions are necessary.
Q5: What strategic considerations should companies address when filing similar patents?
Focus on specific structural features, innovative synthesis methods, or unique therapeutic applications to strengthen patent validity and avoid infringement.
References
- Wang, S., et al. (2021). Asia-Pacific patent trends in neuropharmacological compounds. Journal of Patent Studies, 15(3), 245-268.
- Hong Kong Intellectual Property Department. (2022). Patent Examination Guidelines.
- Liu, T., & Chen, Y. (2020). Patent landscape analysis of neurodegenerative disease treatments. World Patent Review, 9(4), 133-152.
